Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Microbes Infect ; 20(6): 346-352, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29842983

RESUMEN

Host factors are required for efficient HIV-1 replication. To identify these factors, genome-wide RNA interference screening was performed using a human T cell line. In the present study, we assessed whether eukaryotic translation initiation factor 4A isoform 2 (eIF4A2), a DEAD-box protein identified in our screen, is necessary for efficient HIV-1 replication. Exploiting MT4C5 cells depleted of eIF4A2 by stable expression of eIF4A2-specific short-hairpin RNA (shRNA) using a lentiviral system, we found that depletion of eIF4A2 markedly inhibited the infection of a replication-competent reporter HIV-1. eIF4A2 depletion reduced the efficiency of viral cDNA synthesis with virion entry into target cells being unaffected. Depletion of eIF4A2 also inhibited HIV-1 spreading infection in a knockdown level-dependent manner. These results suggest that HIV-1 requires eIF4A2 for optimal replication in human T cells.


Asunto(s)
Factor 4A Eucariótico de Iniciación/metabolismo , Infecciones por VIH/enzimología , VIH-1/fisiología , Interacciones Huésped-Patógeno , Replicación Viral , Linfocitos T CD4-Positivos/enzimología , Linfocitos T CD4-Positivos/virología , Línea Celular , ADN Viral/biosíntesis , Factor 4A Eucariótico de Iniciación/química , Factor 4A Eucariótico de Iniciación/deficiencia , Factor 4A Eucariótico de Iniciación/genética , Silenciador del Gen , Infecciones por VIH/virología , Humanos , ARN Interferente Pequeño/genética
2.
Biochem Biophys Res Commun ; 459(2): 288-293, 2015 Apr 03.
Artículo en Inglés | MEDLINE | ID: mdl-25727021

RESUMEN

Despite remarkable advances in combination antiretroviral therapy (cART), human immunodeficiency virus type 1 (HIV-1) infection remains incurable due to the incomplete elimination of the replication-competent virus, which persists in latent reservoirs. Strategies for targeting HIV reservoirs for eradication that involves reactivation of latent proviruses while protecting uninfected cells by cART are urgently needed for cure of HIV infection. We screened medicinal plant extracts for compounds that could reactivate the latent HIV-1 provirus and identified a procyanidin trimer C1 derived from Theobroma cacao as a potent activator of the provirus in human T cells latently infected with HIV-1. This reactivation largely depends on the NF-κB and MAPK signaling pathways because either overexpression of a super-repressor form of IκBα or pretreatment with a MEK inhibitor U0126 diminished provirus reactivation by C1. A pan-PKC inhibitor significantly blocked the phorbol ester-induced but not the C1-induced HIV-1 reactivation. Although C1-induced viral gene expression persisted for as long as 48 h post-stimulation, NF-κB-dependent transcription peaked at 12 h post-stimulation and then quickly declined, suggesting Tat-mediated self-sustainment of HIV-1 expression. These results suggest that procyanidin C1 trimer is a potential compound for reactivation of latent HIV-1 reservoirs.


Asunto(s)
Biflavonoides/farmacología , Cacao/química , Catequina/farmacología , VIH-1/efectos de los fármacos , Proantocianidinas/farmacología , Provirus/efectos de los fármacos , Activación Viral/efectos de los fármacos , Biflavonoides/química , Biflavonoides/aislamiento & purificación , Catequina/química , Catequina/aislamiento & purificación , Línea Celular , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/metabolismo , Infecciones por VIH/virología , VIH-1/genética , VIH-1/fisiología , Interacciones Huésped-Patógeno/efectos de los fármacos , Humanos , Indoles/farmacología , Células Jurkat , Sistema de Señalización de MAP Quinasas , Maleimidas/farmacología , Pruebas de Sensibilidad Microbiana , Modelos Biológicos , FN-kappa B/metabolismo , Fitoterapia , Plantas Medicinales/química , Proantocianidinas/química , Proantocianidinas/aislamiento & purificación , Proteína Quinasa C/antagonistas & inhibidores , Proteína Quinasa C/metabolismo , Inhibidores de Proteínas Quinasas/farmacología , Provirus/fisiología , Latencia del Virus/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA